Investigational drug · Phase 3
MB11
Also called: Proposed Nivolumab Biosimilar
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced (Unresectable or Metastatic) Melanoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "MB11"
First trial start
2025
Dec 29, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MB11", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced (Unresectable or Metastatic) Melanoma
Largest trials
Live from ClinicalTrials.gov: studies naming "MB11" as an intervention, largest first.
- Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] MelanomaPivotal-lookingRecruiting
mAbxience Research S.L.Industry
NCT07221734 · 632 participants (planned) · Start Dec 29, 2025 · Primary completion Apr 2027
Drug: MB11 (Proposed Nivolumab Biosimilar); EU-Opdivo® and 1 more · For: Advanced (Unresectable or Metastatic) Melanoma
Sites: Banja Luka, Bosnia and Herzegovina; Sarajevo, Bosnia and Herzegovina; Zenica, Bosnia and Herzegovina · 86 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Bulk Segregant Analysis Integrated with Transcriptomic and Proteomic Approaches Reveals Candidate Genes Associated with Drought Tolerance in Cotton.
Tian Y, Zhao Z, Dong Y, et al. · Biology (Basel) 2026
- Computational design of an ultrapotent deltacoronavirus miniprotein inhibitor.
Avery NG, Yoshiyama CN, Taylor AL, et al. · Proc Natl Acad Sci U S A 2026
- Evaluation of the techno-functional properties of lactobacilli strains originated from Bos indicus and Bubalus bubalis calves for probiotic potential.
Kumar S, Chauhan N, Chauhan T, et al. · Int Microbiol 2025
- Developmental outcomes of small infants at a high-risk clinic: A short-term longitudinal study.
Macaskill TA, Du Toit M, Eccles R, et al. · S Afr J Commun Disord 2025
- Computational Elucidation of a Monobody Targeting the Phosphatase Domain of SHP2.
Wang Y, Qiao X, Zhu R, et al. · Biomolecules 2025
- Identification of candidate exposure biomarkers for acetyl tributyl citrate and acetyl triethyl citrate using suspect screening in human liver microsomes.
Choi H, Jo EK, Kwon J, et al. · Environ Int 2024
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.